Literature DB >> 31057683

Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies.

Minh Thanh La1, Van Hieu Tran1, Hee-Kwon Kim1.   

Abstract

Radiometals have been commonly used in medical applications, and utilization of such metals continues to be an attractive research area. In particular, a variety of radiometals have been developed and implemented for molecular imaging. For such applications, 89Zr has been one of the most interesting radiometals currently used for tumor targeting. Several chemical ligands were developed as 89Zr chelators, and new coordinating methods have also been developed more recently. In addition, immuno-positron emission tomography (PET) studies using 89Zr-labeled monoclonal antibodies have been performed by several scientists. In this review, recent advances to the coordination of 89Zr and the utilization of 89Zr in PET studies are described.

Entities:  

Keywords:  89Zr; Coordination; Ligand; Positron emission tomography (PET)

Year:  2019        PMID： 31057683      PMCID： PMC6473018          DOI： 10.1007/s13139-019-00584-z

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  50 in total

Review 1.  Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals.

Authors:  S Liu; D S Edwards
Journal:  Bioconjug Chem       Date:  2001 Jan-Feb       Impact factor: 4.774

Review 2.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Excitation functions of (alpha,xn) reactions on (nat)Rb and (nat)Sr from threshold up to 26 MeV: possibility of production of (87)Y, (88)Y and (89)Zr.

Authors:  S A Kandil; I Spahn; B Scholten; Z A Saleh; S M M Saad; H H Coenen; S M Qaim
Journal:  Appl Radiat Isot       Date:  2007-01-30       Impact factor: 1.513

4.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

Authors:  Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

5.  Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.

Authors:  Pontus K E Börjesson; Yvonne W S Jauw; Ronald Boellaard; Remco de Bree; Emile F I Comans; Jan C Roos; Jonas A Castelijns; Maria J W D Vosjan; J Alain Kummer; C René Leemans; Adriaan A Lammertsma; Guus A M S van Dongen
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

6.  Implementation of 89Zr production and in vivo imaging of B-cells in mice with 89Zr-labeled anti-B-cell antibodies by small animal PET/CT.

Authors:  Martin Walther; Peter Gebhardt; Philipp Grosse-Gehling; Lydia Würbach; Ingo Irmler; Stephan Preusche; Muhammad Khalid; Thomas Opfermann; Thomas Kamradt; Jörg Steinbach; Hans-Peter Saluz
Journal:  Appl Radiat Isot       Date:  2011-03-02       Impact factor: 1.513

7.  89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Authors:  Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis
Journal:  J Nucl Med       Date:  2010-07-21       Impact factor: 10.057

8.  Standardized methods for the production of high specific-activity zirconium-89.

Authors:  Jason P Holland; Yiauchung Sheh; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2009-07-29       Impact factor: 2.408

9.  89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.

Authors:  Iris Verel; Gerard W M Visser; Ronald Boellaard; Marijke Stigter-van Walsum; Gordon B Snow; Guus A M S van Dongen
Journal:  J Nucl Med       Date:  2003-08       Impact factor: 10.057

10.  p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.

Authors:  Lars R Perk; Maria J W D Vosjan; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-18       Impact factor: 9.236
View more
  5 in total

1.  Comparison of the Tissue Distribution of a Long-Circulating Glucagon-like Peptide-1 Agonist Determined by Positron Emission Tomography and Quantitative Whole-Body Autoradiography.

Authors:  Eduardo Felipe Alves Fernandes; Jonas Wilbs; Rene Raavé; Christian Borch Jacobsen; Hanne Toftelund; Hans Helleberg; Milou Boswinkel; Sandra Heskamp; Magnus Bernt Frederik Gustafsson; Inga Bjørnsdottir
Journal:  ACS Pharmacol Transl Sci       Date:  2022-06-30

2.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

3.  Design, Synthesis, Computational, and Preclinical Evaluation of natTi/45Ti-Labeled Urea-Based Glutamate PSMA Ligand.

Authors:  Kristina Søborg Pedersen; Christina Baun; Karin Michaelsen Nielsen; Helge Thisgaard; Andreas Ingemann Jensen; Fedor Zhuravlev
Journal:  Molecules       Date:  2020-03-02       Impact factor: 4.411

4.  State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET.

Authors:  Marion Chomet; Guus A M S van Dongen; Danielle J Vugts
Journal:  Bioconjug Chem       Date:  2021-05-11       Impact factor: 4.774

Review 5.  Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?

Authors:  Tal Burt; Ad F Roffel; Oliver Langer; Kirsten Anderson; Joseph DiMasi
Journal:  Clin Transl Sci       Date:  2022-04-21       Impact factor: 4.438
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.